Commercialized biomarkers: New horizons in prostate cancer diagnostics

Expert Review of Molecular Diagnostics

Volumn 15, Issue 4, 2015, Pages 491-503

  Murphy, Lisa ^a   Prencipe, Maria ^a   Gallagher, William M ^a   Watson, R William ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

clinical utility; commercialized prostate cancer tests; false negative biopsy dilemma; patented biomarkers; prostate cancer screening

Indexed keywords

AMINO ACID; BIOLOGICAL MARKER; CD45 ANTIGEN; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 8; EPITHELIAL CELL ADHESION MOLECULE; KALLIKREIN; KALLIKREIN 2; KI 67 ANTIGEN; MITOCHONDRIAL DNA; MULTIENZYME COMPLEX; UNCLASSIFIED DRUG; UNTRANSLATED RNA; DIAGNOSTIC KIT; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SCREENING; CELL CYCLE PROGRESSION; CIRCULATING TUMOR CELL; CLINICAL FEATURE; DECISION MAKING; DIGITAL RECTAL EXAMINATION; DNA METHYLATION; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE COST; HUMAN; IMMUNOASSAY; INTERMEDIATE RISK PATIENT; METASTASIS; OUTCOME ASSESSMENT; PATIENT PREFERENCE; PREDICTIVE VALUE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER PROGNOSTIC TEST; QUALITY OF LIFE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TRANSURETHRAL RESECTION; BIOPSY; DIAGNOSTIC KIT; ECONOMICS; GENETICS; MALE; MASS SCREENING; METABOLISM; PROCEDURES; PROGNOSIS; PROSTATIC NEOPLASMS; REPRODUCIBILITY; STANDARDS;

BIOMARKERS, TUMOR; BIOPSY; HUMANS; MALE; MASS SCREENING; PROGNOSIS; PROSTATIC NEOPLASMS; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS;

EID: 84925611519     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2015.1011622     Document Type: Review

References (84)

1. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer, Lyon, France; 2013;Available from: www. globocan.iarc.fr [Accessed on 19 February 2014]
2. Anon. Prevention and Treatment of Prostate Cancer: Technologies and Global Markets. BCC Research 2013
3. Murphy L, Watson RW. Patented prostate cancer biomarkers. Nat Rev Urol 2012;9: 464-72
4. Vickers A, Cronin AM, Aus G, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med 2008;6:19
5. Vickers A, Cronin AM, Aus G, et al. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated PSA: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. Cancer 2010;116:2612-20
6. Benchikh A, Savage C, Cronin A, et al. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. BMC Cancer 2010;10:635
7. Vickers A, Cronin AM, Roobol MJ, et al. A Four-Kallikrein Panel Predicts Prostate Cancer in Men with Recent Screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res 2010;16:3232
8. Gupta A, Roobol MJ, Savage CJ, et al. A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands. Br J Cancer 2010;103:708-14
9. Vickers A, Cronin A, Roobol M, et al. Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: an Independent Replication. J Clin Oncol 2010;28:2493-8
10. Vickers A, Cronin A, Roobol M, et al. A Panel of Kallikrein Marker Predicts Prostate Cancer in a Large, Population-Based Cohort Followed for 15 Years without Screening. Cancer Epidemiol Biomarkers Prev 2011;20:255
11. Clinical diagnostics. Available from: www.metabolon.com/diagnostics/ProstateCancer.aspx
12. McDunn JE, Li Z, Adam KP, et al. Metabolomic signatures of aggressive prostate cancer. Prostate 2013;73:1547-60
13. Sokoll LJ, Wang Y, Feng Z, et al. [-2] proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol 2008;180:539-43
14. Jansen FH, van Schaik RH, Kurstjens J, et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010;57:921-7
15. Le BV, Griffin CR, Loeb S, et al. [-2] Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 2010;183:1355-9
16. Kronz JD, Allan CH, Shaikh AA, Epstein JI. Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol 2001;25:1079-85
17. PCA3. Available from: www.pca3.org/pro/labs [Last accessed on 05 June 2014]
18. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59: 5975-9
19. Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-15
20. De Kok JB, Verhaegh GW, Roelofs RW, et al. DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002;62:2695-8
21. Fradet Y, Saad F, Aprikian A, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004;64(2): 311-16
22. Tinzl M, Marberger M, Horvath S. DD3/PCA3 RNA analysis in urine a new perspective for detecting prostate cancer. Eur Urol 2004;46:182-7
23. Groskopf J, Auhin SMJ, Deras IL. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006;52:1089-95
24. Gittelman MC, Hertzman B, Bailen J, et al. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol 2013;190: 64-9
25. FDA approval letter for Progensa(R) PCA3 assay. February 13 2012. Available from: www.accessdata.fda.gov/cdrh-docs/pdf10/p100033a.pdf [Last accessed on 04 March 2014]
26. MDx health. Available from: www.mdxhealth.com
27. Henrique R, Jeronimo C, Teixeira MR, et al. Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Mol Cancer Res 2006;4:1-8
28. Trock BJ, Brotzman MJ, Mangold LA, et al. Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int 2012;110: 56-62
29. Partin AW, Van Neste L, Klein EA, et al. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol 2014;192(4): 1081-7
30. Robinson K, Creed J, Reguly B, et al. Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay. Prostate Cancer Prostatic Dis 2010;13:126-31
31. Parr RL, Martin LH. Mitochondrial and nuclear genomics and the emergence of personalized medicine. Hum Genomics 2012;6:3
32. Prolaris. Available from: www.prolaristest.com
33. Whitfield ML, Sherlock G, Saldanha AJ, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 2002;13:1977-2000
34. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009
35. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-9
36. Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005;102:3738-43
37. Sotiriou C, Desmedt C. Gene expression profiling in breast cancer. Ann Oncol 2006; 17(Suppl 10):259-62
38. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-72
39. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26
40. Cuzick J, Swanson GP, Fisher G, et al. on behalf of the Transatlantic Prostate Group. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes for recurrence and death from prostate cancer: A retrospective study in two cohorts. Lancet Oncol 2011;12: 245-55
41. Freedland SJ, Gerber L, Reid J, et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys 2013;86:848-53
42. Cuzick J, Berney DM, Fisher G, et al. Transatlantic Prostate Group. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 2012;106:1095-9
43. Cooperberg MR, Simko JP, Cowan JE, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 2013;31:1428-34
44. Genomichealth. Available from: https://online.genomichealth.com [Last accessed on 05 June 2014]
45. Shak S, Baehner FL, Maddala T, et al. Method for using gene expression to determine prognosis of prostate cancer. US Patent Application 20120028264. 2012
46. Shak S, Lee M, Novotnyet W, et al. Gene expression profile algorithm and test for determining prognosis of prostate cancer. US0196321; 2013
47. Cooperberg M, Simko J, Falzarano S, et al. Development and validation of the biopsy-based prostate score (GPS) as a predictor of high-grade or extracapsular to improve patient selection for active surveillance [abstract 2131] American Urological Association Annual Meeting; 2013
48. Van der Kwast TH. Prognostic prostate tissue biomarkers of potential clinical use. Virchows Arch 2014;464:293-300
49. Gordon DJ, Resio B, Pellman D. Causes and consequences of aneuploidy in cancer. Nat Rev Genet 2012;13:189-203
50. OPKO Lab. Available from: www.ourlab. net/OURView-Prognostic-Panel.asp [Last accessed 05 June 2014]
51. Decipher. Available from: http://genomedx. com/decipher/overview/[Last accessed on 05 June 2014]
52. Erho N, Crisan A, Vergara IA, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One 2013;8:e66855
53. Ross AE, Feng FY, Ghadessi M, et al. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer Prostatic Dis 2013;17:64-9
54. Karnes JR, Bergstralh EJ, Davicioni E, et al. Validation of a Genomic Classifier that Predicts Metastasis Following Radical Prostatectomy in an At Risk Patient Population. J Urology 2013;190:2047-53
55. Badani K, Thompson DJ, Buerki C, et al. Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget 2013;4:600-9
56. Irispermed. Available from: www.irispermed. com [Last accessed on 05 June 2014]
57. Moul JW, Lilja H, Semmes OJ, et al. NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy. Urology 2012;80: 319-25
58. Cellsearch. Available from: www.cellsearchctc.com
59. Shaffer DR, Jia X, de Bono JS, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Can Res 2007;13:2023-9
60. Danila DC, Heller G, Gignac GA, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13: 7053-8
61. Chen BT, Loberg RD, Neeley CK, et al. Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. Urology 2005;65:616-21
62. Moreno JG, Miller MC, Gross S, et al. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 2005;65:713-18
63. de Bono JS, Scher HI, Montgomery RB, et al. Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 2008;14:6302-9
64. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-90
65. Prostate Cancer Foundation, 2013. Moving beyond the PSA debate. Available form www.pcf.org/site/c.leJRIROrEpH/b.5955299/k.E214/Moving-Beyond-the-PSA-Debate.htm
66. Huber F, Montani M, Sulser T, et al. Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer-what has gone wrong? A blueprint for the way forward in biomarker studies. Br J Cancer 2015;112(1): 140-8
67. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nature Clinical Practice Oncology 2005;2:416-22
68. O'Hurley G, Sjöstedt E, Rahman A, et al. Garbage in, garbage out: a critical evaluation of strategiesused for validation of immunohistochemical biomarkers. Mol Oncol 2014;8(4):783-98
69. Voigt JD, Zappala S, Vaughan ED, Wein AJ. The Kallikrein Panel for prostate cancer screening: its economic impact. Prostate 2014;74:250-9
70. Nichol MB, Wu J, An JJ, et al. Budget impact analysis of a new prostate cancer risk index for prostate cancer detection. Prostate Cancer Prostatic Dis 2014;14:253-61
71. Fowler JE Jr, Bigler SA, Miles D, Yalkut DA. Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer. J Urol 2000;163:813-18
72. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68-80
73. Djavan B, Zlotta A, Remzi M, et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1, 051 men. J Urol 2000;163:1144-8
74. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol 2002;167:2435-9
75. Welch HG, Fisher ES, Gottlieb DJ, Barry MJ. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst 2007;99:1395-400
76. Hoffman RM, Denberg T, Hunt WC, Hamilton AS. Prostate cancer testing following a negative prostate biopsy: over testing the elderly. J Gen Intern Med 2007;22:1139-43
77. Tombal B, Andriole GL, de la Taille A, et al. Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy? Urology 2013;81:998-1004
78. Shore N, Concepcion R, Saltzstein D, et al. Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. Curr Med Res Opin 2013;30: 547-53
79. Crawford ED, Scholz MC, Kar AJ, et al. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Curr Med Res Opin 2014;30:1025-31
80. Swanson GP, Riggs M, Hermans M. Pathologic findings at radical prostatectomy: risk factors for failure and death. Urol Oncol 2007;25:110-14
81. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 2009;281:1591-7
82. Riethdorf S, Fritsche H, Müller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system. Clin Cancer Res 2007;13:920-8
83. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-904
84. Sturgeon C, Hill R, Hortin GL, Thompson D. Taking a new biomarker into routine use-A perspective from the routine clinical biochemistry laboratory. Proteomics Clin Appl 2010;4:892-903